BD Promotes Dave Hickey to Executive VP and President, Life Sciences Segment
October 22, 2020: See Original Post (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the promotion of Dave Hickey to executive vice president and president, Life Sciences segment, effective January 1, 2021.
Succeeding Kaltenbach as executive vice president and president of the Life Sciences segment is Dave Hickey, 57, who currently serves as worldwide president of the Integrated Diagnostics Solutions business. As president of the Life Sciences segment, Hickey will oversee the Biosciences, Preanalytical Systems and Diagnostics Systems businesses worldwide.
“I’m confident Dave is the right successor to lead the Life Sciences segment at this critical time for the industry and for public health,” said Polen. “Throughout nearly 30 years of experience in the life sciences field, Dave has consistently delivered high performance and he has proven himself as an empathetic, passionate and transformative leader of customer-centric teams. Dave’s leadership in the Diagnostics space has been on full display during the pandemic, as his team rallied around our purpose and delivered innovative laboratory and point-of-care COVID-19 testing solutions in record time.”
Hickey joined BD in 2014 as vice president and general manager for the Clinical Microbiology business and was promoted to president of the Diagnostics Systems business in 2016. Prior to BD, Hickey spent 22 years with Siemens Healthcare Diagnostics in multiple positions of increasing responsibility. Hickey began his career as a clinical biochemist in the United Kingdom.
Hickey will report to Polen.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com.
|Kristen Cardillo||Kristen M. Stewart, CFA|
|BD Public Relations||BD Investor Relations|
Latest posts by Chris Frew (see all)
- Gyroscope Therapeutics, which has operations in King of Prussia, raises $148M - March 31, 2021
- TCR² Therapeutics Acquires Cell Therapy Manufacturing Facility & New VP of Technical Operations, Aaron Vernon - March 29, 2021
- Frederick Based Biotech Law Firm McBee Moore & Vanik IP, LLC Celebrates Five Years - February 18, 2021
- Heather Mudrick Joins Workforce Genetics to Lead Clinical Search Practice - February 12, 2021
- RNA Disease Diagnostics, Inc. Takes Exclusive License to Cutting-Edge Molecular RNA Diagnostic Platform Technology from UMB and UMBC - February 4, 2021